November 2009 · Vol. 58, No. 12
Incretin Therapy: A New Paradigm in the Treatment of Type 2 Diabetes
A CME Webcast
Presented by: — Harold E. Lebovitz, MD, FACE
Professor of Medicine, Department of Medicine, Division of Endocrinology, State University of New York Health Science Center at Brooklyn, Brooklyn, New York
VIEW WEBCAST | TRANSCRIPT
This state-of-the-art webcast will provide a concise, practical, evidence-based overview of type 2 diabetes, the comorbidities associated with type 2 diabetes, the role of incretins, and emerging treatment options.
The incidence of diabetes has reached epidemic proportions, and despite daily monitoring and multiagent treatment regimens, many patients are unable to maintain long-term glycemic control. Clinical research continues to evolve at a breakneck pace, and understanding of new physiologic processes is essential to optimizing the knowledge base. Therefore, to improve the quality of patient care, there is a need for a practical, case-based educational program that provides up-to-date, evidence-based information on type 2 diabetes and appropriate antihyperglycemic therapy.
After participating in this activity, participants should be able to:
Summarize the comorbidities associated with diabetes
Distinguish key pathophysiologic characteristics of diabetes including insulin resistance, beta-cell dysfunction, and incretin abnormalities
Describe the role of incretin hormones in regulating glucose metabolism
Compare the advantages and disadvantages of incretin therapy versus traditional therapies in the treatment of type 2 diabetes
Start date: November 30, 2009
Expiration date: November 30, 2010
The Network for Continuing Medical Education (NCME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
NCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Provided by the Network for Continuing Medical Education (NCME).
This activity is supported by an educational grant from Amylin Pharmaceuticals, Inc. and Eli Lilly and Company.
The Network for Continuing Medical Education (NCME) requires that CME faculty disclose, during the planning of an activity, the existence of any personal, financial, or other relationships they or their spouses/partners have with the commercial supporter of the activity or with the manufacturer of any commercial product or service discussed in the activity. The disclosure is in the presentation slides.
The Journal of Family Practice ©2009 Quadrant HealthCom Inc.